Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Short Interest Update

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 1,187,068 shares, an increase of 56.6% from the November 30th total of 758,068 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 577,313 shares, the days-to-cover ratio is presently 2.1 days. Based on an average daily trading volume, of 577,313 shares, the days-to-cover ratio is presently 2.1 days. Currently, 0.2% of the company’s shares are sold short.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Several institutional investors and hedge funds have recently made changes to their positions in FMS. Pzena Investment Management LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 1.0% in the third quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock worth $390,128,000 after purchasing an additional 153,870 shares during the last quarter. Todd Asset Management LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 5.2% in the third quarter. Todd Asset Management LLC now owns 1,303,424 shares of the company’s stock worth $34,319,000 after acquiring an additional 64,311 shares during the period. Millennium Management LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 50.0% during the 1st quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock valued at $26,982,000 after buying an additional 361,364 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its position in Fresenius Medical Care AG & Co. KGaA by 8.3% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 816,200 shares of the company’s stock valued at $21,491,000 after acquiring an additional 62,700 shares during the last quarter. Finally, Hennessy Advisors Inc. purchased a new position in Fresenius Medical Care AG & Co. KGaA in the second quarter worth about $11,479,000. Institutional investors own 8.37% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on FMS. Bank of America cut shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a report on Wednesday, October 15th. UBS Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a report on Wednesday, October 15th. Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Zacks Research lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Finally, Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Fresenius Medical Care AG & Co. KGaA presently has an average rating of “Reduce” and an average target price of $30.00.

Fresenius Medical Care AG & Co. KGaA Stock Down 0.0%

NYSE:FMS traded down $0.01 during trading hours on Tuesday, reaching $23.91. 58,146 shares of the company traded hands, compared to its average volume of 377,092. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 0.45. The business’s 50-day moving average price is $24.30 and its two-hundred day moving average price is $25.52. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $22.05 and a 1 year high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.05. The firm had revenue of $5.73 billion during the quarter, compared to the consensus estimate of $4.72 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 7.42% and a net margin of 3.72%. On average, equities research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.